Clinical trials: Natural Killer Cell Malignancies
Analgesia, Breast Cancer
US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation
Prospective interventional study
- Trial name
- NCT04796363
- Testing
- Erector Spinae Plane Block with Bubivacaine, Standard General Anaesthesia
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
Reactivating NK Cells in Treating Refractory Head and Neck Cancer
This study aims to determine the safety and efficacy of expanded activated autologous NK cells administered after cetuximab in patients with EGFR-positive nasopharyngeal carcinoma or head and neck squamous cell carcinoma.
- Trial name
- NKEXPHNC (NCT02507154)
- Testing
- Cetuximab + NK cells
- Where
- Singapore
- Volunteers
- 31 people
- Sponsor
- National University Hospital, Singapore
AML, Adult
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived…
- Trial name
- NCT06367673
- Testing
- iPSC-NK cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhejiang University
AML, Adult
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML).
- Trial name
- NCT05601466
- Testing
- QN-023a, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM [defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase…
- Trial name
- NK2010-35 (NCT01313897)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Non-small Cell Lung Cancer
CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Non - small cell lung cancer ( NSCLC ) accounts for more than 80% of lung cancer. The main treatment for early stage patients is surgical resection, but about 30% -70% patients will relapse.
- Trial name
- NCT01533727
- Testing
- Autologous CIK Transfusion plus Chemotherapy, chemotherapy alone
- Where
- China
- Sponsor
- Sun Yat-sen University
Sarcoma
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures
The objectives of the study is to evaluate the anti-tumor activity of autologous natural killer cells in cultures of cancer cells obtained from patient's own tumor.
- Trial name
- NCT05869994
- Where
- United States
- Sponsor
- Sarcoma Oncology Research Center, LLC
Non-small Cell Lung Cancer Metastatic
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.
- Trial name
- NCT03007875
- Testing
- high-activity natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Leukemia, Lymphoma
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
The purpose of this study is to find out how many irradiated natural killer (NK) cells can be safely given to patients with cancer that has recurred after an autologous stem cell transplant, and to see what effects (good and bad)…
- Conditions
- Leukemia, Lymphoma, Myeloma, Hodgkin's Disease
- Trial name
- NCT00990717
- Testing
- NK-92 cells
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Merkel Cell Carcinoma
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR.
- Trial name
- NCT03853317
- Testing
- Avelumab, N-803, haNK™
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Hepatocellular Carcinoma
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
The goal of this clinical trial is to explore the efficacy and safety of autologous iNKT cells in patients with progressed hepatocellular carcinoma (HCC) after treatment with PD-1 antibody.
- Trial name
- NCT05962450
- Testing
- iNKT Cells, PD-1, Regorafenib
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Beijing YouAn Hospital
Acute Myeloid Leukemia, Leukemia
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes
- Trial name
- NCT06138587
- Testing
- Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Dana-Farber Cancer Institute
Cervical Cancer
p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management
The objective of this study is to evaluate the outcome of cervical intraepithelial neoplasia grade 2 (CIN-II) patients followed up without treatment for 24 months according to p16 and ki-67 immunohistochemical staining and to the…
- Trial name
- NCT02522585
- Testing
- Conservative management
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy.
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
- Trial name
- SOLID-NK (NCT07589530)
- Testing
- EB-NK-301, Fludarabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
This phase I trial studies the side effects and best dose of expanded natural killer cells in treating younger patients with brain tumors that have come back or do not respond to treatment.
- Conditions
- Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
- Trial name
- NCT02271711
- Testing
- Laboratory Biomarker Analysis, Natural Killer Cell Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma, Recurrent, Refractory
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer…
- Trial name
- NCT06751134
- Testing
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Nanjing Children's Hospital
Non-small Cell Lung Cancer
Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based immunotherapy in subjects with non small cell lung cancer.
- Trial name
- NCT03198923
- Testing
- natural killer and natural killer T cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Wenxiang Wang
Hepatocellular Carcinoma
By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy
To prove that the efficacy and safety of 'NK group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(RFA or operation) for hepatocellular carcinoma in China.
- Trial name
- NCT02725996
- Testing
- NK cells, Curative therapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Southwest Hospital, China